Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Dean Sheppard

University of California, San Francisco, Department: Internal Medicine/medicine

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Pliant Therapeutics

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

NA

Listed Research Project
Interventional Targeting of the IRE1alpha-TGFbeta signaling loop in pulmonary fibrosis

PROJECT NARRATIVE Patients with pulmonary fibrosis have evidence of activation of a stress response in the lungs called the unfolded protein response; this response normally plays an important role in protecting cells, such as epithelial cells and fibroblasts, from being overwhelmed by demands to make more proteins, but in the face of excessive demands the unfolded protein response can lead to cellular dysfunction, inappropriately-high protein secretion, and eventually cell death. We have developed a novel class of drugs that inhibits these destructive consequences of the unfolded protein response and found these drugs protect mice in two different models of pulmonary fibrosis. In the current proposal we will determine the mechanisms underlying the contributions of the unfolded protein response to pulmonary fibrosis and how our novel drugs protect lung epithelial cells and fibroblasts; this work should provide insights into key steps in the development of pulmonary fibrosis and should provide a roadmap for developing novel treatments for fibrotic diseases in general.

Filed on March 13, 2019.

Tell us what you know about Dean Sheppard's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Dean Sheppard University of California, San Francisco Conflict of Interest Pliant Therapeutics $60,000 - $79,999
Dean Sheppard University of California, San Francisco Conflict of Interest Pliant Therapeutics $0 - $4,999
Name Institution Type Company Disclosed Value
Dean Sheppard University of California, San Francisco Financial Disclosure Pliant Therapeutics, Inc.
Dean Sheppard University of California, San Francisco Financial Disclosure Pliant Therapeutics, Inc.
Dean Sheppard University of California, San Francisco Financial Disclosure Pliant Therapeutics, Inc.
Dean Sheppard University of California, San Francisco Financial Disclosure Pliant Therapeutics, Inc.
Dean Sheppard, Md University of California, San Francisco Financial Disclosure Pliant Therapeutics, Inc.
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page